Vernalis says completes CCP-07 pivotal single-dose comparative bioavailability study

21 December 2015

UK-based Vernalis (LSE: VER) on Monday said it has completed the pivotal single-dose comparative bioavailability study for its drug candidate to treat cough and cold.

The company said CCP-07, is the second product being developed for Vernalis by Tris Pharma for the US prescription cough cold market. The first product, Tuzistra XR (codeine polistirex and chlorpheniramine polistirex) was approved by the US Food and Drug Administration in April 2015 and was launched by Vernalis in September 2015.

Ian Garland, chief executive of Vernalis, said: “We are delighted with the continued progress of CCP-07 which further demonstrates the low-development risk of our cough cold pipeline in development with Tris, and we look forward to further news flow from these programs, over the coming months”.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK